Neuland Labs FY26 PAT Rises 40% to ₹363.1 Crore

• Neuland Laboratories reported Q4FY26 PAT surge of 666.3% YoY to ₹212.5 crore on a 134.9% revenue growth to ₹788.7 crore.
• FY26 full-year PAT increased 40% YoY to ₹363.1 crore with total income up 37.1% to ₹2,053.1 crore, driven by CMS business scale-up.
• The company invested ₹397 crore in capex for peptide manufacturing and a new R&D center, maintaining a net cash position of ₹156.8 crore.